ArticleCancer research communications2025

A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors.

Kenneth B DeSantes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.